Abrilumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Abrilumab
Monoclonal antibody
Type?
SourceHuman
Targetintegrin alpha-4 beta-7
Clinical data
Other namesAMG 181
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6362H9806N1686O2014S52
Molar mass143.8 kg/mol g·mol−1

Abrilumab (INN;[1] development code AMG 181) is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn's disease.[2]

This drug was developed by MedImmune.

References[edit]

  1. ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Abrilumab, American Medical Association.